SEC Form 4 · accession 0001209191-17-067088
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P Richard
Director
Period of report
Dec 20, 2017
Accepted (ET)
Dec 22, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Redeemable Convertible NoteF2,F3 | $9.19 | Dec 20, 2017 | J | — | D | — | — | Common Stock | 58 | — | D |
Explanation of responses
- F1Reflects a redeemable convertible note of the Issuer (the "Note") that was called for redemption by the Reporting Person at a price equal to its face value.
- F2At the option of the Reporting Person, at any time on or before February 19, 2018, the Note shall be redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively.
- F3The Note will mature on February 19, 2018.